Reduction in vaccine-type human papillomavirus prevalence among women in the United States, 2009-2012

Journal of Infectious Diseases

Volumn 214, Issue 12, 2016, Pages 1961-1964

  Berenson, Abbey B ^a   Haque Laz, Tabassum ^a   Rahman, Mahbubur ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

HPV vaccine; Human papillomavirus; Prevalence; Young adults

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; TREND STUDY; UNITED STATES; VACCINATION; VIRUS STRAIN; WART VIRUS; WOMEN'S HEALTH; ADOLESCENT; CLASSIFICATION; CROSS-SECTIONAL STUDY; GENETICS; GENOTYPE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; UNITED STATES; YOUNG ADULT;

EID: 85016066317     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw515     Document Type: Article

References (15)

1. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR RecommRep 2014; 63:1-30.
2. Anhang Price R, Tiro JA, Saraiya M, Meissner H, Breen N. Use of human papillomavirus vaccines among young adult women in the United States: an analysis of the 2008 National Health Interview Survey. Cancer 2011; 117:5560-8.
3. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:997-1001.
4. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208:385-93.
5. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 2016; 137:1-9.
6. Centers for Disease Control and Prevention. Adult vaccination coverage-United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:66-72.
7. Williams WW, Lu PJ, O'Halloran A, et al. Noninfluenza vaccination coverage among adults-United States, 2012. MMWR Morb Mortal Wkly Rep 2014; 63:95-102.
8. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years-United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:685-93.
9. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1705-8.
10. Steinau M, Onyekwuluje JM, Scarbrough MZ, Unger ER, Dillner J, Zhou T. Performance of commercial reverse line blot assays for human papillomavirus genotyping. J Clin Microbiol 2012; 50:1539-44.
11. Steinau M, Swan DC, Unger ER. Type-specific reproducibility of the Roche linear array HPV genotyping test. J Clin Virol 2008; 42:412-4.
12. Yu S, Kwon MJ, Lee EH, Park H, Woo HY. Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus. J Med Virol 2015; 87:1587-93.
13. Levi AW, Bernstein JI, Hui P, Duch K, Schofield K, Chhieng DC. A comparison of the Roche Cobas HPV test with the Hybrid Capture 2 test for the detection of high-risk human papillomavirus genotypes. Arch Pathol Lab Med 2016; 140:153-7.
14. Attanasio L, McAlpine D. Accuracy of parental reports of children's HPV vaccine status: implications for estimates of disparities, 2009-2010. Public Health Rep 2014; 129:237-44.
15. Saville AM. Cervical cancer prevention in Australia: planning for the future. Cancer Cytopathol 2016; 124:235-40.